Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep, she was trying to be clever, blew up in her face and she's been ousted!
Did I miss something? Last I saw the Board change request had rejected as illegal.
Suzy wont sort anything out Porky and as well you know. She was given her marching orders.
So you want 10 evaluations at £100 k a pot then after BOD salary leaves you with zero money to pay for lab staff or to invest in CLX. If there is no lab then you need to pay to outsource the compounds which cost more.
Your finance calculations are as bad as it was when you invested in 4D.
Constantly changing BOD is not going to change the outcomes. The outcomes need to be achieved. Changes only slows things down but then again you are not invested.
Yes and if focus had been on cancer drug dev rather than a Poxy lab start up just to maintain salary and bonus benefits for the board as an ongoing lifestyle business I might agree with you. The handling of 201 a specific example of how bad the management has been.
A p poor director does not wake up the next day and suddenly become a good one. Sorry but until the board changes happen my view remains this is uninvestable. And the longer it takes the worse it will get.
The best out come here is to clear the deck, remove the deadwood have a new board with focus on what matters, reduce cash burn back to under £1.5m and have this in situ ready for H2. At that point the new BOD with that vision could raise and drive it forwards.
If that doesn’t happen and all the current BOD drainers remain this will either close completely as it won’t secure further shareholder capital to continue or Suzy will secure death spiral finance to extend it that bit longer and then it will close completely.
Having no clinical trials doesn't seem to be pulling in the crowds either.
My reason for investing in Valirx is purely because of the low risk strategy. No clinical trials and looking for an early deal that would offer significant upfront payment and milestones.
If the strategy changed in the future I would be out. I don't believe that funding clinical trials on AIM would result in a return in investment in most cases especially in a bearish market.
'Valirx is not at that stage yet and also not full of institutional investors.'
PM clearly looks forward to the day that VAL can be like REDX (and delist from AIM). Maybe he has overlooked that REDX are down 66% today?
Bit stupid to make a like for like comparison. They will probably list on Nasdaq so they have access to greater funds to fund the many 10s of millions they require to fund late stage trials which is very hard to raise on the AIM.
Valirx is not at that stage yet and also not full of institutional investors.
It does mean less competition and hopefully less choice. If outcomes are positive Valirx could move big.
@HD
Utter nonsense - The BOD and ONLY the BOD are culpable for the current state of this penny share due to the past history of dire decisions made. They have run it into the ground.
There is however a chink of light, should the appropriate board changes get sorted ready for H2. Until then the stock remains uninvestable but there is always hope the changes will come in time to avoid a Redx situation.
Just vile, the pair of you. It's clear to everyone else what you 2 are up to, but with a Bio stock trying to help cancer treatments, the morals of the pair of you is second to none. Just Vile.
@HD
Oh grab a sense of humour, have a bit more of your egg.
Geez, you and Slater are out in force on ad vfn Porky. For a couple of chaps not invested/not interested in investing you are both certainly hammering the bbs. Wonder why that may be? pond scum, the pair of you.
@Ratcliffewriter
Loved your Norwegian Blue analogy to 201 - classic, lol.
Owner: Oh yes, the, uh, the Norwegian Blue...What's,uh...What's wrong with it?
Mr. Praline: I'll tell you what's wrong with it, my lad. 'E's dead, that's what's wrong with it!
Owner: No, no, 'e's uh,...he's resting.
Mr. Praline: Look, matey, I know a dead parrot when I see one, and I'm looking at one right now.
Owner: No no he's not dead, he's, he's restin'! Remarkable bird, the Norwegian Blue, idn'it, ay? Beautiful plumage!
Where's the quarterly update Suzy? You may not give 2 sh#tes now you have been shown the door, but you are still CEO for the time being, so do your job. Still totally confident and unconcerned love?
'At the moment nothing really is priced in.'
No - continued failure and dilutatory finance with a supportive shareholder base is priced in. What happens when many people stop believing and buying more shares to average down?
The hope is that 201 will get signed before the next placing or we get some positive CLX news/deal, Lab contracts positive evaluation outcomes that increase the valuation .
Likely 15/20 million market cap if 201 signed. All depends and all relative to results/outcomes. At the moment nothing really is priced in.
'A 2 million cash burn is nothing'? Unless it happens to represent over 40 percent of the company's entire market capital, and the bulk of it is spent on wages.
As for 201 phase 2 trial being 'completed', they might have a hope of that if they'd actually started. 201 has been gathering dust for almost 3 and a half years. It looks more like the Norwegian Blue parrot than anything else.
Two years out of date and counting.
DId I say 201 phase 2 trials were completed? If you are so worried about the peer review maybe look at Astrazeneca.
I invested based on the potential to get the compounds moving making it far more valuable and hopefully with a few deals. Not based on the finished product.
We are a better investment than any other biotech because raising 20/30/40 million in this market for clinical trials probably means a delisting. The lack of risk vs reward should see Val being one of the few that actually does very well. A 2 million cash burn is next to nothing compared to others to be fair as long as they can show some value.
Https://www.telegraph.co.uk/business/2023/10/31/ftse-100-markets-news-mortgages-latest/
30th November 2020 (almost 3 and a half years ago) on the full results from 201 - 'Additional detailed analysis of the results will form the basis of peer-reviewed journal publications.'
You're the enthusiast, I'm the potential investor. Where is the 'additional detailed analysis? Where are the peer reviews? You say 201 is some sort of transformational game changer, I think it's a dead duck. Convince me otherwise, because for now you just look like a soot-juggling ramper trying to pump this to reduce losses.
We are not at that stage of peer reviews. We don't do clinical trials and have not completed a preclinical project yet. Nothing to conclude but potential is strong based on what is out in the public.
https://www.valirx.com/cytolytix-limited
https://www.dundee.ac.uk/stories/new-method-discovered-halt-active-cancer-cells
Compound from Imperial needs no introduction as to how good that would be.
Other than 201, we are investing in the hope that one of these compounds can get a large preclinical deal. Clearly all these show enough promise to indicate they will get through the early stages.
'The science work.....has been really good.'
Can you give me a summary of scientific progress over the last 24 months, preferably with links to RNSs and peer reviews?
Well changes have been made. I never stated everyone should be removed but would have been in favour of a change with a shareholder on the BOD. I just don't see how widespread changes can make anything better or make it faster. It slows it down as we can all see now.
All that matters is outcomes. Even though I am significantly down I think that is more down to a lack of commercial skills on the BOD but I guess that is the reason why the action group picked Adrian otherwise why bother because he has no real experience in this work. The science work and control of finances has actually been really good and the foundations are strong.